Profusa had a vision for its Lumee™ Oxygen Platform to be used in patients with potential acute and/or chronic changes in tissue oxygen levels who may benefit from continuous monitoring.
Before it could be commercially available, Profusa had a key issue to resolve with the wearable reader of its injectable hydrogel sensor.
“Ten years ago, you couldn’t build a reader that could sense multiple signals and filter out the ‘noise’ of the body’s other signals, all while being small and skin-worn,” explains Ben Hwang, CEO of Profusa. “With the latest advancements in flexible hybrid electronics technology, it’s just mature enough to work the way we want — primarily because we selected the right domain expertise partner to work with, namely NextFlex.”